Australia markets closed

Eli Lilly and Company (LLY)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
203.82-0.70 (-0.34%)
At close: 4:04PM EST

204.21 +0.39 (0.19%)
Pre-market: 5:12AM EST

Full screen
Trade prices are not sourced from all markets
Previous close204.52
Open203.57
Bid199.63 x 1000
Ask206.32 x 1000
Day's range201.75 - 205.55
52-week range117.06 - 218.00
Volume2,132,729
Avg. volume4,329,243
Market cap195.346B
Beta (5Y monthly)0.28
PE ratio (TTM)30.02
EPS (TTM)6.79
Earnings date27 Apr 2021
Forward dividend & yield3.40 (1.67%)
Ex-dividend date11 Feb 2021
1y target est216.14
  • Welldoc and Lilly collaborate to integrate BlueStar® app capabilities into Lilly's connected insulin solutions
    PR Newswire

    Welldoc and Lilly collaborate to integrate BlueStar® app capabilities into Lilly's connected insulin solutions

    Welldoc, Inc., and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc's software into Lilly's connected insulin solutions, currently in development. Under the terms of the agreement, Lilly and Welldoc will collaborate to create a new version of the BlueStar® insulin management solution that integrates insulin dosing data for several Lilly insulins. Lilly will commercialize the pen platform, which will include the new app and Lilly's connected insulin pen solutions.

  • Lilly to Participate in Cowen Health Care Conference
    PR Newswire

    Lilly to Participate in Cowen Health Care Conference

    Eli Lilly and Company (NYSE: LLY) will participate in the Cowen and Company 41st Annual Health Care Conference on Thursday, March 4, 2021. Daniel Skovronsky, M.D., Ph.D., Lilly's Chief Scientific Officer and President of Lilly Research Laboratories, will participate in a fireside chat at 9:10 a.m., Eastern Time.

  • 3 Reasons Rigel Pharmaceuticals Stock Can Continue Soaring
    Motley Fool

    3 Reasons Rigel Pharmaceuticals Stock Can Continue Soaring

    Shares of Rigel Pharmaceuticals (NASDAQ: RIGL) recently popped after the company announced a collaboration deal with one of America's largest drugmakers, Eli Lilly (NYSE: LLY). A new collaboration deal with a big pharmaceutical company isn't the only reason to keep an eye on this often overlooked biotech stock. Here's why investors can look forward to outstanding returns from Rigel Pharmaceuticals in the years to come.